Until now, no methods have been validated for the determination of neurotoxic effects or for the evaluation of metabolism-mediated hazards of chemical substances. The current test guidelines are based on studies in vivo, involving animals exposed to the test substance. In the EU White Paper on a Strategy for a Future Chemicals Policy, which may result in up to 30,000 chemicals being screened for toxicity, the use of non-animal test methods is seen as essential and is encouraged. The aim of the present work was to demonstrate the significance of novel technologies, including the use of genetically engineered cell lines and three-dimensional cell culture techniques for direct application in the regulatory hazard-assessment process, with an emphasis on metabolism-mediated toxicity and neurotoxicity.
BlaauboerB.J., BoobisA.R., CastellJ.V., CoeckeS., GroothuisG.M.M., GuillouzoM.A., HallT.J., HawksworthG.M., LorenzonG., MiltenburgerH.G., RogiersV., SkettP., VillaP., & WiebelF.J. (1994). The practical applicability of hepatocyte cultures in routine testing. The report and recommendations of ECVAM workshop 1. ATLA22, 231–241.
2.
WiebelF.J., AnderssonT.B., CascianoD.A., DickinsM., FischerV., GlattH., HorbachJ., LangenbachR.J., LuytenW., TurchiG., & VandewalleA. (1997). Genetically engineered cell lines: characterisation and applications in toxicity testing. Report and recommendations of ECVAM workshop 26. ATLA25, 625–639.
3.
CoeckeS., RogiersV., BaylissM., CastellJ., DoehmerJ., FabreG., FryJ., KernA., & WestmorelandC. (1999). The use of long-term hepatocyte cultures for detecting induction of drug metabolising enzymes: the current status. ECVAM Hepatocyte and Metabolically Competent Systems Task Force Report 1. ATLA27, 579–638.
4.
BallsM., BlaauboerB.J., FentemJ.H., BrunerL., CombesR.D., EkwallB., FielderR.J., GuillouzoA., LewisR.W., LovellD.P., ReinhardtC.A., RepettoG., SladowskiD., SpielmannH., & ZuccoF. (1995). Practical aspects of the validation of toxicity test procedures. Report and recommendations of ECVAM workshop 5. ATLA23, 129–147.
5.
BallsM., & KarcherW. (1995). The validation of alternative test methods. ATLA23, 884–886.
6.
CurrenR.D., SoutheeJ.A., SpielmannH., LiebschM., FentemJ.H., & BallsM. (1995). The role of prevalidation in the development, validation and acceptance of alternative methods. ECVAM Prevalidation Task Force Report 1. ATLA23, 211–217.
7.
FentemJ.H., ArcherG.E.B., BallsM., BothamP.A., CurrenR.D., EarlL.K., EsdaileD.J., HolzhütterH.G., & LiebschM. (1998). The ECVAM international validation study on in vitro tests for skin corrosivity. 2. Results and evaluation by the Management Team. Toxicology in Vitro12, 483–524.
8.
SpielmannH., BallsM., DupuisJ., PapeW.J., PechovitchG., de SilvaO., HolzhütterH.G., ClothierR., DesolleP., GerberickF., LiebschM., LovellD., MaurerT., PfannenbeckerU., PotthastJ.M., CsatoM., SladowskiD., SteilingW., & BrantomP. (1998). The international EU/COLIPA in vitro phototoxicity validation study: results of Phase II (blind trial): part I: the 3T3 NRU phototoxicity test. Toxicology in Vitro12, 305–327.
9.
Cooper-HannanR., HarbellJ.W., CoeckeS., BallsM., BoweG., CervinkaM., ClothierR., HermannF., KlahmL.K., de LangeJ., LiebschM., & VanparysP. (1999). The principles of Good Laboratory Practice: application to in vitro toxicological studies. Report and recommendations of ECVAM workshop 37. ATLA27, 539–577.
10.
BullS., LangezaalI., ClothierR., & CoeckeS. (2001). A genetically engineered cell-based system for detecting metabolism-mediated toxicity. ATLA29, 703–716.
11.
CoeckeS., BogniA., LangezaalI., WorthA., HartungT., & MonshouwerM. (2001). The use of genetically engineered cells for assessing CYP2D6-related polymorphic effects. Toxicology in Vitro15, 553–556.
12.
Le CluyseE.L. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. European Journal of Pharmaceutical Sciences13, 343–368.
13.
AtterwillC.K., BruininkA., DrejerJ., DuarteE., AbdullaE.M., MeredithC., NicoteraP., ReganC., Rodríguez-FarréE., SimpsonM.G., SmithR., VeronesiB., VijverbergH., WalumE., & WilliamsD.C. (1994). In vitro neurotoxicity testing. Report and recommendations of ECVAM workshop 3. ATLA22, 350–362.
14.
StingeleS., NicoteraP.L., BallsM., & CoeckeS. (1999). Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing. Patent No. 99402139.2-2106/International No PCT/EP00/08223. Deposited with the European Patent Office, Munich, Germany.
15.
HoneggerP., & SchilterB. (1992). Serum-free aggregate cultures of fetal rat brain and liver cells: methodology and some practical applications in neurotoxicology. In The Brain in Bits and Pieces. In Vitro Techniques in Neurobiology, Neuropharm-acology and Neurotoxicology (ed ZbindenG.), pp. 51–79. Zollikon, Switzerland: MTC Verlag.
16.
EskesC., HoneggerP., Juillerat-JeanneretL., & Monnet-TschudiF. (2002). Microglial reaction induced by noncytotoxic methylmercury treatment leads to neuroprotection via interaction with astro-cytes and IL-6 release. Glia37, 43–52.
17.
EskesC., Juillerat-JeanneretL., LeubaG., HoneggerP., & Monnet-TschudiF. (2003). Involvement of microglia-neuron interactions in the TNF-α release, microglial activation and neurodegeneration induced by trimethyltin. Journal of Neuroscience Research, in press.
